{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T09:36:15Z","timestamp":1773308175266,"version":"3.50.1"},"reference-count":24,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2010,6,10]],"date-time":"2010-06-10T00:00:00Z","timestamp":1276128000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2010,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>We analyzed the correlation between well\u2010established biological parameters of prognostic relevance in B\u2010cell chronic lymphocytic leukemia (CLL) [i.e. mutational status of the immunoglobulin heavy chain variable region (IgVH), ZAP\u201070 and CD38 expression] and serum levels of B cell\u2013activating factor (BAFF of the TNF family) by evaluating the impact of these variables on the time to first treatment (TFT) in a series of 169 previously untreated CLL patients in Binet stage A. Higher levels of BAFF were more frequently associated with female gender (<jats:italic>P\u2003<\/jats:italic>=\u20030.02), younger age (<jats:italic>P\u2003<\/jats:italic>=\u20030.01), Rai stage 0 (<jats:italic>P\u2003<\/jats:italic>=\u20030.002), higher platelet count (<jats:italic>P\u2003<\/jats:italic>=\u20030.005), mutated IgVH disease (<jats:italic>P\u2003<\/jats:italic>=\u20030.002), higher occurrence of normal cytogenetic profile or presence of 13q deletion (<jats:italic>P\u2003<\/jats:italic>=\u20030.02), low ZAP\u201070\u2010 (<jats:italic>P\u2003<\/jats:italic>=\u20030.003), and CD38\u2010expression (<jats:italic>P\u2003<\/jats:italic>=\u20030.02). Maximally selected log\u2010rank statistic plot identified a serum BAFF concentration of 0.313\u2003ng\/mL as the best cut\u2010off (<jats:italic>P\u2003<\/jats:italic>&lt;\u20030.0001). This threshold recognized two subsets of patients with different TFT (<jats:italic>P\u2003<\/jats:italic>&lt;\u20030.0001). Because in multivariate analysis soluble BAFF [Hazard ratio (HR), 8.23; confidence Interval (CI) 95%,3.0\u201322.6, <jats:italic>P\u2003<\/jats:italic>&lt;\u20030.0001] and mutational status of IgVH (HR\u2003=\u20032.60; CI 95% 1.10\u20136.14, <jats:italic>P\u2003<\/jats:italic>=\u20030.03) maintained the discriminating power their combined effect on clinical outcome was assessed. When three groups were considered: (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"#b1\">1<\/jats:ext-link>) low\u2010risk (<jats:italic>n\u2003<\/jats:italic>=\u200393), patients with concordant IgVH<jats:sub>mut<\/jats:sub> and higher soluble BAFF; (<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"#b2\">2<\/jats:ext-link>) intermediate\u2010risk (<jats:italic>n\u2003<\/jats:italic>=\u200350), patients with IgVH<jats:sub>mut<\/jats:sub> and low BAFF levels or IgVH<jats:sub>unmut<\/jats:sub> and soluble higher BAFF;(<jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" xlink:href=\"#b3\">3<\/jats:ext-link>) high\u2010risk (<jats:italic>n\u2003<\/jats:italic>=\u200326), patients with concordant IgVH <jats:sub>unmut<\/jats:sub> and low soluble BAFF, the 2\u2010yr TFTs were, respectively, 95%, 85%, and 41% (<jats:italic>P\u2003<\/jats:italic>&lt;\u20030.0001). In conclusion, our results indicate that in early B\u2010cell CLL, the biological profile including among other parameters soluble BAFF may provide a useful insight into the complex interrelationship of prognostic variables.<\/jats:p>","DOI":"10.1111\/j.1600-0609.2010.01482.x","type":"journal-article","created":{"date-parts":[[2010,6,10]],"date-time":"2010-06-10T22:11:44Z","timestamp":1276207904000},"page":"314-320","source":"Crossref","is-referenced-by-count":25,"title":["Baff serum level predicts time to first treatment in early chronic lymphocytic leukemia"],"prefix":"10.1111","volume":"85","author":[{"given":"Stefano","family":"Molica","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanna","family":"Digiesi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caterina","family":"Battaglia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanna","family":"Cutrona","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Antenucci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matteo","family":"Molica","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana","family":"Giannarelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabella","family":"Sperduti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Gentile","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fortunato","family":"Morabito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manlio","family":"Ferrarini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2010,6,10]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.285.5425.260"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V97.1.198"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrd1982"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-02-0558"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0301-472X(01)00774-3"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-06-2043"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.02.7938"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2008.05.004"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.10317"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2009.03.030"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V87.12.4990.bloodjournal87124990"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-06-093906"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/eji.200526355"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2000.18.13.2607"},{"key":"e_1_2_5_16_2","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1182\/blood.V78.4.895.895","article-title":"Progression and survival studies in early chronic lymphocytic leukemia","volume":"78","author":"Molica S","year":"1991","journal-title":"Blood"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0167-9473(02)00225-6"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200012283432602"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2008.03.003"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2567.2006.02377.x"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-02-0540"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-06-027755"},{"key":"e_1_2_5_24_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21328"},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.1080\/10428190903013334"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1600-0609.2010.01482.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1600-0609.2010.01482.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T01:24:51Z","timestamp":1697419491000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1600-0609.2010.01482.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6,10]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["10.1111\/j.1600-0609.2010.01482.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1600-0609.2010.01482.x","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,6,10]]}}}